圆素品牌怎么样 申请店铺

我要投票 圆素在胶原蛋白行业中的票数:499 更新时间:2025-12-14
圆素是哪个国家的品牌?「圆素」是 包头东宝生物技术股份有限公司 旗下著名品牌。该品牌发源于内蒙古,由创始人王军在1997-03-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力圆素品牌出海!将品牌入驻外推网,定制圆素品牌推广信息,可以显著提高圆素产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

圆素怎么样

包头东宝生物技术股份有限公司成立于1997年,是一家专业的生物制品国家级高新技术企业。主营“金鹿”牌明胶、“圆素”牌胶原蛋白及“白云”牌磷酸氢钙产品。公司注册资本近2亿元,拥有总资产约5亿元。

公司2011年7月6日在深圳证券交易所成功上市,股票简称“东宝生物”,股票代码“300239”,是内蒙古自治区第一家在创业板上市的民营企业,也是包头市第一家登陆国内A股的民营企业。

公司技术中心早在2001年就被认定为自治区级技术中心。公司通过了ISO9001国际质量体系认证、HACCP食品安全管理体系认证。2010年东宝生物获中国日用化工协会明胶分会颁发2005-2009年度全国明胶行业先进企业荣誉;2010年获国家发改委授予“国家高技术产业化示范工程”牌匾;2012年,可溶性胶原蛋白研发及产业化项目获内蒙经信委颁发自治区乌兰夫基金企业技术创新奖;2012年,公司获第一财经中国资本力年会颁发年度最佳融资范例奖、年度最佳创业板IPO上市公司荣誉;2013年,获内蒙质监局、内蒙出入境检验检疫局、内蒙药监局等16家单位联合颁发的内蒙古“2012年全国质量月产品质量用户满意度调查用户满意单位”荣誉证书。2013年获内蒙党委、政府认定为内蒙古自治区非公有制科学发展先进企业。

2010年,东宝生物与中科院理化所历时两年多时间共同开发出千位级道尔顿“圆素”牌小分子量骨胶原蛋白肽,生产技术获中国发明专利(专利号:ZL200910241882.X)。“圆素”牌胶原蛋白肽产品经SGS国际权威机构检测,平均分子量约在1300道尔顿,产品质量指标达到国际同类产品先进水平,属高品质胶原蛋白产品。系列粉剂、果汁饮品、面膜、眼膜、眼霜等产品上市以来,以其过硬的产品质量赢得了国际、国内消费者和下游客户的广泛认可和赞誉。升级后的新包装以及VI新形象品味独特,健康和美丽蕴含其间,品牌效应逐步显现。公司目前生产的胶原蛋白产品及在研的后续产品符合国家最新发布的《关于促进健康服务业发展的若干意见》和《中国食物与营养发展纲要(2014—2020年)》支持方向,具有良好的发展前景。

公司拥有行业内首家产学研合作研发机构——“中科院理化所—东宝生物胶原与明胶生物工程应用研发中心”,技术力量雄厚。已经开始的《不同分子量胶原蛋白肽促骨生长活性研究》、《基于静电纺丝技术明胶纳米纤维无纺布的制备及用途研究》、《600吨/年骨素酶法明胶生产中试线的工艺研究项目》等项目进展顺利,将对拓展企业主营业务、提升核心竞争力产生积极提升和推进作用。

2012年12月,公司以自有资金1000万元出资的全资子公司东宝圆素(北京)科贸有限责任公司成立。该公司主要负责胶原蛋白系列产品全国范围内的销售。

2013年10月,公司在内蒙古自治区政府统一安排部署下,在美国洛杉矶“中美省州经贸合作研讨会”上与美国的LipondInternational和Pureorg公司签订了战略合作框架合约。在此基础上,2013年12月东宝生物与LipondInternational在中国包头又签订了《原材料采购合约》,与Pureorg公司签订了《服务合作协议书》,通过pureorg同UCLA(加州大学洛杉矶分校)进行胶原蛋白及胶原蛋白衍生品对抑制肿瘤的研究,并研发相应复合型配方胶原蛋白产品,开启了“圆素”牌胶原蛋白大步走向国际市场的新局面。

据相关媒体分析,未来我国胶原蛋白年需求量有望达到2万吨,市场空间有望进一步加速放大,市场前景十分广阔。

公司作为新兴生物制品企业,主营业务符合国家促进生物产业、战略性新兴产业等政策扶持方向,属国家重点支持的行业。良好的政策环境为企业实现快速发展创造了前所未有的条件。公司地处内蒙古,拥有丰富的骨料资源,立足高档生物制品的专业化生产,借助资本市场的融资手段,打造稳健发展、持续增长的生物制品企业,为我国生物产业做出新的贡献,为人类对健康和美的追求作出最大的贡献。

Baotou Dongbao Biotechnology Co., Ltd., founded in 1997, is a professional national high-tech enterprise of biological products. Main products are "Jinlu" brand gelatin, "Yuansu" brand collagen and "Baiyun" brand calcium hydrogen phosphate products. The company has a registered capital of nearly 200 million yuan and a total asset of about 500 million yuan. The company was successfully listed in Shenzhen Stock Exchange on July 6, 2011. The stock is called "Dongbao biology" for short, with the stock code of "300239". It is the first private enterprise listed on the growth enterprise market in Inner Mongolia Autonomous Region, and the first private enterprise listed on the domestic A-share market in Baotou city. As early as 2001, the company's technology center was recognized as an autonomous region level technology center. The company has passed ISO9001 international quality system certification and HACCP food safety management system certification. In 2010, Dongbao biology was awarded the honor of 2005-2009 national advanced enterprise in gelatin industry by gelatin branch of China Daily Chemical Industry Association; in 2010, Dongbao biology was awarded the plaque of "national high technology industrialization demonstration project" by national development and Reform Commission; in 2012, soluble collagen R & D and industrialization project was awarded the technology innovation award of WuLanfu fund enterprise by Inner Mongolia Economic and Information Commission; In 2012, the company won the annual best financing example award and the annual best gem IPO listed company honor issued by China capital power annual meeting of first finance and economics; in 2013, the company won the Inner Mongolia "2012 national quality month product quality customer satisfaction survey user satisfaction unit" honorary certificate jointly issued by Inner Mongolia Quality Supervision Bureau, Inner Mongolia entry exit inspection and Quarantine Bureau, Inner Mongolia Drug Administration and other 16 units. In 2013, it was recognized by the Party committee and the government of Inner Mongolia as an advanced enterprise of non-public scientific development in Inner Mongolia Autonomous Region. In 2010, it took more than two years for Dongbao biology and Institute of physics and chemistry of Chinese Academy of Sciences to jointly develop thousands of Dalton "Yuansu" brand small molecular weight bone collagen peptide, and the production technology was patented in China (Patent No.: zl200910241882. X). "Yuansu" brand collagen peptide products have been tested by SGS international authority. The average molecular weight is about 1300 Dalton. The product quality index has reached the international advanced level of similar products. It is a high-quality collagen product. Products such as series of powder, juice drinks, facial mask, eye mask and eye cream have been widely recognized and praised by international and domestic consumers and downstream customers for their excellent product quality. After upgrading, the new packaging and VI image taste are unique, health and beauty are contained in them, and the brand effect gradually appears. The company's current collagen products and follow-up products under research are in line with the support direction of several opinions on promoting the development of health service industry and China's food and Nutrition Development Program (2014-2020), which are newly released by the state, and have a good development prospect. The company has the first industry university research cooperation R & D institution in the industry - "Institute of physics and chemistry of Chinese Academy of Sciences - Dongbao biological collagen and gelatin bioengineering application R & D center", with strong technical force. The projects such as research on bone growth promoting activity of different molecular weight collagen peptide, research on the preparation and application of Gelatin Nanofiber non-woven fabric based on electrostatic spinning technology, and Research on the process of 600 t / a bone enzyme gelatin production pilot line are progressing smoothly, which will play an active role in expanding the main business and promoting the core competitiveness of the enterprise. In December 2012, Dongbao Yuansu (Beijing) science and Trade Co., Ltd., a wholly-owned subsidiary of the company with its own capital of 10 million yuan, was established. The company is mainly responsible for the nationwide sales of collagen products. In October 2013, under the unified arrangement and deployment of Inner Mongolia Autonomous Region government, the company signed a strategic cooperation framework contract with lipond international and pureorg company of the United States at the "Sino US provincial economic and trade cooperation seminar" in Los Angeles. On this basis, in December 2013, Dongbao biology and lipond international signed a raw material purchase contract in Baotou, China, and a service cooperation agreement with pureorg company. Through pureorg and UCLA, they carried out research on the inhibition of tumor by collagen and collagen derivatives, and developed corresponding compound collagen products, It has opened a new situation that "Yuansu" brand collagen strides to the international market. According to the analysis of relevant media, the annual demand for collagen in China is expected to reach 20000 tons in the future, the market space is expected to further accelerate the expansion, and the market prospect is very broad. As a new biological product enterprise, the main business of the company is in line with the national policy support direction of promoting biological industry and strategic emerging industry, and it is a key industry supported by the state. A good policy environment has created unprecedented conditions for the rapid development of enterprises. The company is located in Inner Mongolia, with rich aggregate resources, based on the specialized production of high-end biological products, with the help of financing means of capital market, to build a stable development and sustainable growth of biological products enterprises, to make new contributions to China's biological industry, and to make the greatest contribution to the pursuit of health and beauty.

本文链接: https://brand.waitui.com/d2cd7a313.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

应对老年护理刚需,四部门发布《老年护理服务能力提升行动方案》

近日,国家卫生健康委、国家医保局、国家中医药局和国家疾控局四部门发布《老年护理服务能力提升行动方案》(以下简称《行动方案》)提出,到2027年,老年护理资源有效扩容,覆盖机构、社区、居家的老年护理服务体系逐步完善,从业人员服务能力不断提升,老年护理服务持续改善,服务连续性、可及性、规范性持续提高,老年人获得感不断增强。提升老年护理服务能力是深入贯彻实施积极应对人口老龄化国家战略的具体举措。截至2024年底,我国60岁及以上人口数达3.1亿,占总人口的22%,老年人特别是失能老年人对医疗护理服务呈现迫切的刚性需求。(央视新闻)

26分钟前

消息人士称英伟达考虑提高H200芯片产量

消息人士称,英伟达考虑提高H200芯片产量。(新浪财经)

26分钟前

中国造高端工业母机在沈阳下线交付

记者13日从通用技术沈阳机床获悉,由通用技术集团与东方电气集团联合研发的4台高端五轴联动数控机床12日在沈阳下线交付。这一合作在取得重大技术突破的同时,还打破了“研用脱节”的产业困境,开创了国产工业母机研制的新模式。长期以来,国产高端数控机床面临“研发投入大、周期长、验证难”的系统性瓶颈——企业闭门研发与市场实际需求脱节,产品因缺乏真实工况下的长期验证,陷入“用户不愿用、不敢用,技术难迭代、难成熟”的恶性循环,严重制约产业高质量发展。(中新网)

26分钟前

金融时报:将坚持内需主导放在首位

金融时报评论员发布文章称,12月10日至11日,中央经济工作会议在京举行。会议聚焦“当前怎么看”和“明年怎么干”,为中国经济高质量发展把舵定向。站在“十四五”规划收官与“十五五”规划谋篇的历史交汇点,会议强调持续扩大内需、优化供给,将“坚持内需主导,建设强大国内市场”确定为明年经济工作重点任务之首。未来一个时期,我国国内市场主导国民经济循环的特征将更为明显。在内外部发展环境更趋严峻复杂的大背景下,只有坚持立足国内,全方位扩大内需、建设强大国内市场,增强发展主动性,才能够在国际风云变幻中,牢牢把握发展主动权。着眼明年经济社会发展目标任务,做强国内大循环,建设强大国内市场,以国内循环的稳定性对冲国际循环的不确定性,必须坚持内需的主导地位。坚持内需主导,全方位扩大国内需求,要大力提振居民消费。坚持内需主导,全方位扩大国内需求,要推动投资止跌回稳。将坚持内需主导放在首位,是党和国家对当前经济形势的深刻洞察。要全面贯彻明年经济工作的总体要求和政策取向,加快培育完整内需体系,形成消费和投资相互促进的良性循环,将超大规模市场的潜力转化为现实增长动力。

26分钟前

脑虎科技:公司“三全”脑机接口产品成功完成首例临床试验

在今日举行的2025天桥脑科学研究院脑机接口与人工智能论坛中,脑虎科技方面表示,公司自主研发的国内首款、国际第二款内置电池的全植入、全无线、全功能(“三全”)脑机接口产品,在复旦大学附属华山医院毛颖、陈亮教授团队的主持下,成功完成首例临床试验。(财联社)

26分钟前

本页详细列出关于圆素的品牌信息,含品牌所属公司介绍,圆素所处行业的品牌地位及优势。
咨询